Actively Recruiting
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Led by Lapo Alinari · Updated on 2026-02-27
18
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This phase I trial tests the safety, side effects, and best dose of tegavivint in treating patients with large b-cell lymphomas that has come back (relapsed) or does not respond to treatment (refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tegavivint may help control the disease.
CONDITIONS
Official Title
Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed or refractory germinal center B-cell-like or non-GCB diffuse large B-cell lymphoma with c-Myc and BCL2 expression or translocation
- Diagnosed with relapsed/refractory high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations
- Histologic transformation of indolent non-Hodgkin's lymphoma to diffuse large B-cell lymphoma
- At least two prior systemic therapies received
- Ineligible for or refused stem cell transplant or CAR-T therapy, or received these treatments at least 3 months prior
- Age 18 years or older
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Measurable disease by PET scan with at least one site measurable by standardized uptake value
- Absolute neutrophil count of 500/mcL or higher
- Platelet count of 25,000/mcL or higher
- Total bilirubin less than or equal to 1.5 times the upper normal limit
- AST and ALT less than 3 times the institutional upper normal limit
- Creatinine clearance at least 60 ml/min by Cockcroft-Gault formula
- Able and willing to give written informed consent and comply with study procedures
- Women of child-bearing potential and sexually active men must use effective contraception during and for 4 months after treatment
You will not qualify if you...
- Allergic reactions to tegavivint or similar agents
- Active central nervous system lymphoma or CNS involvement not in remission for at least 3 months
- Chronic active hepatitis B or C infection
- HIV positive patients on combination antiretroviral therapy with excluded medications
- History of active tuberculosis
- Major surgery within 3 weeks before starting treatment
- Uncontrolled heart disease or corrected QT interval over 480 msec
- Uncontrolled infections or illnesses
- Psychiatric or social conditions limiting compliance
- Pregnant or breastfeeding women
- Abnormal serum chemistry values considered clinically significant by investigator
- Personal history of malignancy except certain low-risk or treated cancers in remission for at least 3 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
T
The Ohio State Comprehensive Cancer Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here